Science1 publisherNot yet confirmed elsewhere2 min readPublished
GLP-1 users in a self-report survey describe nail detachment four times as often as non-users
Researchers surveying 1,904 people found nail detachment reported by 39% of GLP-1 users and 9% of non-users with diabetes or obesity. About half of the users said they had nail problems before treatment began, so the survey cannot show how much of that gap the drugs caused.
The Scientist · Science desk
What happened
- Researchers set 575 GLP-1 users against a control group of 1,329 people who had type 2 diabetes or obesity but had never used the drugs, recruited in France, the US, Brazil and Mexico.
- The results were presented at the European Academy of Dermatology and Venereology Congress 2026 in Vienna.
- After accounting for skin conditions and nutritional deficiencies, some associations weakened, but detachment and discoloration stayed about two to three times as common among users.
- Participants described their own symptoms at a single point in time, with no standardized dermatological examination, so the design cannot establish that the drugs caused the changes.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- decision A clinician who sees nail separation in a patient on a GLP-1 drug needs that patient's pre-treatment nail history before attributing the problem to the medication.
- constraint The 39% cannot be quoted to patients as their risk on starting treatment, because a one-time prevalence survey does not measure how often the problem begins after the first dose.
- constraint With results pooled across unnamed GLP-1 drugs, prescribers have nothing here to help them choose between products on nail grounds.
Dividing the raw shares gives crude effect sizes. Users reported detachment about 4.3 times as often as controls [22] and discoloration about 2.7 times as often [23]. The broadest measure moves least. At least one nail disorder was reported by 66 percent of users and 53 percent of controls, a 13-point gap and a ratio of about 1.25 [6][24]. To land in the adjusted range the release gives, detachment's ratio had to shrink by roughly a third to a half, while discoloration's crude figure already sat inside that range [26]. The announcement does not include the adjusted estimates or their confidence intervals [15].
Detachment in this survey is a loose category. Separation of the nail plate from its bed is called onycholysis, and DermNet lists injury, skin disease and infection among its causes in fingers or toes [12]. The survey's figure may mix partial separation with complete loss, and fingernails with toenails [11]. As a prevalence figure taken at one moment, the 39 percent cannot be read as a new patient's chance of developing detachment after starting the drug [13].
Weight loss is the confounder most readers will reach for, and the team tested it. Among participants who had lost weight, the differences stayed statistically significant [16]. That argues against weight loss as the whole explanation, but it does not show a direct effect on the nail [16]. A companion analysis of the same participants found unusual hair loss in 50 percent of users against 34 percent of controls, and reduced hair density in 42 percent against 19 percent [17]. Among users, hair loss usually came with itching, redness or scaling [18]. Bruno Halioua, a dermatologist at the Société Française des Sciences Humaines sur la Peau and a study author, suggests that pattern could involve inflammation beyond the shedding typical after rapid weight loss [19]. Because the hair data come from the same people, they do not independently replicate the nail result [20].
The timing result is the one a clinician can act on. About half of the users reported nail problems before treatment began [5]. If the two questions counted the same thing, that is within about 3 points of the 53 percent of controls who report any nail disorder now [25]. On that reading, users started out close to the controls. Charles Taïeb, a study author and managing director of the European Market Maintenance Assessment, made the same point [9]. "Our findings show a clear association, but they also underline an important point," he said. "Not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself." [8]
What to watch
- A peer-reviewed paper with the adjusted ratios and confidence intervals, which would show how tight the excess among users really is.
- A prospective study that examines nails before and after the first dose, the design that could measure how often detachment starts on treatment.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence30
- Adoption
- Insufficient
- Hype gap+10
- Incentives55
- Confidence60
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
A study of 1,904 people across four countries examined whether nail problems were more common among people taking GLP-1 drugs used for obesity and type 2 diabetes.
- [2]
The findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna.
- [3]
Researchers compared 575 GLP-1 users with 1,329 people with type 2 diabetes or obesity who had never used the medications, recruited across France, the United States, Brazil and Mexico.
- [4]
Nail detachment was reported by 39 percent of GLP-1 users, compared with 9 percent of people with type 2 diabetes or obesity who had never taken the drugs.
- [5]
Around half of the drug users reported nail problems before treatment began.
- [6]
According to an EADV press release, 66 percent of users reported at least one nail disorder, compared with 53 percent of controls.
- [7]
Nail discoloration was reported by 46 percent of GLP-1 users versus 17 percent of controls.
- [8]
"Our findings show a clear association, but they also underline an important point." "Not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."
- [9]
Study author Charles Taïeb is the managing director of the European Market Maintenance Assessment.
- [10]
The study relied on participants describing their symptoms and was cross-sectional, capturing experiences at one point rather than following participants through treatment with standardized dermatological examinations, so it cannot establish that the medications caused the changes.
- [11]
The researchers have not specified whether nail detachment covers partial separation from the nail bed, complete nail loss, or both, and available information does not distinguish fingernails from toenails.
- [12]
Separation of the nail plate from its bed is called onycholysis; DermNet explains it can affect fingers or toes and has several causes, including injury, skin disease and infection.
- [13]
The 39 percent figure should not be read as evidence that nearly four in ten users lost their nails completely, and it does not estimate a new patient's chance of developing the problem after starting medication.
- [14]
Researchers accounted for dermatological conditions and nutritional deficiencies; some associations weakened, but nail detachment and discoloration remained around two to three times more frequent among users, according to the release.
- [15]
The exact adjusted estimates and confidence intervals are not provided, so the precision of the comparisons cannot be assessed from the announcement.
- [16]
Differences remained statistically significant when the analysis focused on participants who had lost weight, suggesting weight loss alone might not explain the findings; this does not demonstrate a direct effect on nails.
- [17]
A companion study of the same participants found unusual hair loss in 50 percent of users versus 34 percent of controls, and reduced hair volume or density in 42 percent versus 19 percent.
- [18]
Among users, hair loss was usually accompanied by scalp symptoms such as itching, redness or scaling.
- [19]
Study author and dermatologist Bruno Halioua of the Société Française des Sciences Humaines sur la Peau suggests the hair pattern could go beyond the shedding typically seen after rapid weight loss and involve inflammation.
- [20]
The hair findings came from the same group of people, so they do not independently replicate the nail results.
- [21]
The release does not identify which GLP-1 medications participants took or give results for any specific drug, so the findings cannot establish a nail effect tied to any one drug.
- [22]
Crude ratio of reported nail detachment, users to controls, is about 4.3.
- [23]
Crude ratio of reported nail discoloration, users to controls, is about 2.7.
- [24]
For any nail disorder, the gap between users and controls is 13 percentage points, a ratio of about 1.25.
- [25]
The roughly 50 percent of users reporting pre-treatment nail problems is about 3 points below the 53 percent of controls reporting any nail disorder.
- [26]
Moving from a crude detachment ratio of about 4.3 to the adjusted range of two to three is a reduction of roughly a third to a half; discoloration's crude ratio of 2.7 already lies within that range.
Sources
1 independent publisher whose own reporting we read for this story.
- sciencealert.comSome People Taking Ozempic-Like Drugs Are Reporting Their Fingernails Detaching
1 article · October 8, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.